The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia

Oncogene

Volumn 35, Issue 3, 2016, Pages 279-289

  Giotopoulos, G ^a,b   Chan, W I ^a,b,c   Horton, S J ^a,b   Ruau, D ^a,b   Gallipoli, P ^a,b   Fowler, A ^a   Crawley, C ^a   Papaemmanuil, E ^b   Campbell, P J ^a,d   Gottgens B ^a,b   Van Deursen, J M ^d   Cole, P A ^e   Huntly, B J P ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b University of Cambridge   (United Kingdom)

^c MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^d MAYO CLINIC   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; BONE SIALOPROTEIN (35-62), HUMAN; C646 COMPOUND; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; PEPTIDE FRAGMENT; PYRAZOLE DERIVATIVE; SIALOGLYCOPROTEIN;

ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZOATES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; E1A-ASSOCIATED P300 PROTEIN; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE ACETYLTRANSFERASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; PEPTIDE FRAGMENTS; PYRAZOLES; SIALOGLYCOPROTEINS;

EID: 84955638995     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.92     Document Type: Article

References (36)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907.
2. Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
3. Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012; 367: 647-657.
4. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000; 95: 745-755.
5. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
6. Bedford DC, Kasper LH, Fukuyama T, Brindle PK. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 2010; 5: 9-15.
7. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA 2002; 99: 14789-14794.
8. Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A et al. The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells. Mol Cell Biol 2011; 31: 5046-5060.
9. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
10. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
11. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-252.
12. Roelfsema JH, Peters DJ. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 2007; 9: 1-16.
13. Kung AL, Rebel VI, Bronson RT, Ch'ng LE, Sieff CA, Livingston DM et al. Gene dosedependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000; 14: 272-277.
14. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997; 89: 3945-3950.
15. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M et al. Adenoviral E1Aassociated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23; q13). Blood 1997; 90: 4699-4704.
16. Deguchi K, Ayton P, Carapeti M, Kutok J, Snyder C, Williams I et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 2003; 3: 259-271.
17. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 1999; 19: 764-776.
18. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol Cell Biol 2002; 22: 6542-6552.
19. Bayly R, Chuen L, Currie RA, Hyndman BD, Casselman R, Blobel GA et al. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. J Biol Chem 2004; 279: 55362-55371.
20. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005; 26: 2031-2045.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
22. Oki Y, Issa JP. Epigenetic mechanisms in AML-a target for therapy. Cancer Treat Res 2010; 145: 19-40.
23. Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am 2011; 25: 1215-1233 viii.
24. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-596.
25. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 2010; 17: 471-482.
26. ENCODE Project Consortium, A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9: e1001046.
27. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198-6208.
28. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013; 97: 683-694.
29. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL. Systematic in vivo structure-function analysis of p300 in hematopoiesis. Blood 2009; 114: 4804-4812.
30. Allard S, Masson JY, Cote J. Chromatin remodeling and the maintenance of genome integrity. Biochim Biophys Acta 2004; 1677: 158-164.
31. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013; 33: 2169-2178.
32. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011; 333: 765-769.
33. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH et al. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One 2013; 8: e55481.
34. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLLfusion leukaemia. Nature 2011; 478: 529-533.
35. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
36. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.